SAN DIEGO, July 30, 2026
Contineum Therapeutics, Inc. reported its second-quarter 2026 financial results while reaffirming key clinical development milestones across its pipeline of therapies for inflammatory and fibrotic diseases. The company announced continued expansion of its global Phase 2 PROPEL-IPF trial evaluating PIPE-791 in patients with idiopathic pulmonary fibrosis (IPF), with more than 55 clinical sites now active across eight countries to support enrollment. Contineum also highlighted that Johnson & Johnson completed enrollment in the Phase 2 MOONLIGHT-1 trial evaluating JNJ-5120/PIPE-307 for major depressive disorder (MDD). Alongside its clinical progress, the company streamlined its research operations to prioritize high-potential development programs while maintaining a projected cash runway through mid-2029.
Global Phase 2 IPF Trial Continues Enrollment
The company’s lead clinical program, PROPEL-IPF, is a global, randomized, double-blind, placebo-controlled Phase 2 trial evaluating the efficacy, safety, tolerability, and pharmacokinetics of once-daily oral PIPE-791 in approximately 324 patients with idiopathic pulmonary fibrosis. The study, initiated during the first quarter of 2026, will evaluate treatment over 26 weeks, with the primary endpoint measuring change from baseline in absolute forced vital capacity (FVC). Contineum confirmed that the growing number of participating sites is expected to support a steady pace of patient enrollment. Earlier this year, the company also reported positive Phase 1b topline data for PIPE-791 in chronic osteoarthritis pain and chronic low back pain, where the investigational therapy demonstrated a favorable safety profile and encouraging improvements in pain compared with placebo, supporting continued clinical development in chronic pain indications.
PIPE-307 Program Advances Under Johnson & Johnson Collaboration
Contineum also reported progress in its partnered clinical program JNJ-5120/PIPE-307, with Johnson & Johnson completing enrollment of 107 participants in the Phase 2 MOONLIGHT-1 trial during June 2026. The randomized, double-blind, placebo-controlled study is evaluating the efficacy, safety, and tolerability of the investigational therapy as a monotherapy for major depressive disorder. Meanwhile, the company announced strategic restructuring of its discovery research activities to concentrate resources on inflammatory and fibrotic disease programs. The changes include a limited workforce reduction and the departure of Chief Scientific Officer Daniel Lorrain, Ph.D., as Contineum reallocates research, translational science, and clinical development resources toward its highest-priority pipeline assets.
Advertisement
Financial Position Supports Long-Term Clinical Development
Contineum ended the second quarter with $236.6 million in cash, cash equivalents, and marketable securities, which management believes will fund planned operations through mid-2029, extending approximately one year beyond the anticipated completion of the PROPEL-IPF trial. Research and development expenses decreased 10% year-over-year to $12.7 million, reflecting completion of prior clinical programs, partially offset by increased investment in the PIPE-791 IPF program. General and administrative expenses increased 23% to $4.7 million, primarily due to higher employee-related and stock-based compensation costs. The company reported a net loss of $15.2 million for the second quarter of 2026, compared with $16.0 million during the same period in 2025, underscoring continued financial discipline while advancing multiple clinical-stage programs.
Source: Contineum Therapeutics press release
